Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
NCT ID: NCT00456716
Last Updated: 2010-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
5 participants
INTERVENTIONAL
2007-03-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BATTLE Program: Sorafenib in Patients With NSCLC
NCT00411671
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00182689
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
NCT01159327
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00098540
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00754923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sorafenib
400mg po bid
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy \> 12 weeks
* Biopsy-proven BAC or adenocarcinoma
* Willing to provide smoking status
* Selected IIIB or stage IV cancer that is incompletely resected or unresectable
Exclusion Criteria
* Pregnant or nursing women
* Surgery or radiation therapy within 4 weeks of starting study
* Major heart condition within 6 months of starting therapy
* Certain concomitant medications prohibited
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Amgen
INDUSTRY
Swedish Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Swedish Medical Center, Swedish Cancer Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Howard J West, M.D.
Role: PRINCIPAL_INVESTIGATOR
Swedish Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swedish Cancer Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRC 0639
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.